Monarch Community Bancorp, Inc. Announces the Successful

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Monarch Community Bancorp, Inc. Announces the Successful Raising of $16.5 Million in Investor Funds and Corporate Restructuring

COLDWATER, Mich., Oct. 2, 2013 (GLOBE NEWSWIRE) -- Monarch Community Bancorp, Inc. (OTCQB:MCBF), the parent company of Monarch Community Bank, today announced it has successfully raised $16.5 million in investor funds which will be used to purchase approximately 8,250,000 shares of Monarch Community Bancorp's newly issued common stock at $2.00 per share. The funds will remain in escrow pending the completion of all documentation associated with the Company's retirement of U.S. Department of Treasury TARP obligations and the closing of the transaction, which is expected to conclude in the next 30 to 45 days.

"We are very gratified at the response of the investment community," stated Richard J. DeVries, President and CEO of Monarch Community Bancorp and Monarch Community Bank, "and are most appreciative of the leadership provided by our investment bankers at the firms of Donnelly Penman & Partners and Boenning & Scattergood, Inc.

Funds will be used to recapitalize Monarch Community Bank, to retire approximately $8.2 million in U.S. Department of Treasury TARP obligations for approximately $4.4 million, and to support the ongoing growth of the bank.

The Bank also announced a corporate restructuring that will streamline the organization, enhance loan production capacity and result in approximately $1.3 million in annualized expense reductions. Approximately $1.0 million of these reductions will be generated through reduced personnel expense. "These are difficult decisions to make and to implement," stated DeVries, "but they will allow us to operate with an expense structure that will be more in line with our peer banks across the state of Michigan."  

Monarch Community Bank is headquartered in Coldwater, Michigan and operates five full service retail offices in Branch, Calhoun and Hillsdale counties and nine loan production offices in Kalamazoo, Calhoun, Berrien, Ingham, Lenawee, Kent, Livingston and Jackson counties in Michigan and one in Steuben County, Indiana.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934 as amended. Monarch intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and is including this statement for purposes of these safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Monarch, are generally identified by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," or "project" or similar expressions. Monarch's ability to predict results, or the actual effect of future plans or strategies, is inherently uncertain. Factors which could have a material adverse effect on the operations and future prospects of Monarch and the subsidiaries include, but are not limited to, changes in: interest rates; general economic conditions; legislative/regulatory changes; monetary and fiscal policies of the U.S. government, including policies of the U.S. Treasury and the Federal Reserve Board; the quality and composition of the loan or securities portfolios; demand for loan products; deposit flows; competition; demand for financial services in Monarch's market areas; Monarch's implementation of evolving technologies; and accounting principles, policies, and guidelines. These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

For additional information, visit Monarch Community Bancorp's website at www.monarchcb.com .

Richard J. DeVries, CEO (517) 279-3978 Rebecca S. Crabill, CFO (517) 279-3956

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 23

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 32

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kotak Mahindra Bank's Innovative Tech Strategies

Updated Category News Views 587

Kotak Mahindra Bank's Commitment to Digital Transformation Kotak Mahindra Bank is at the forefront of revolutionizing financial services through its innovative technology strategies. Their latest report dives deep into the bank's extensive tech activities, highlighting how it leverages digital transformation to enhance customer experience and streamline operations....

Continue Reading
Star Group, L.P. Reflects on Fiscal 2024 Performance Updates

Updated Category News Views 349

Star Group's Fiscal 2024 Insights and Performance Analysis As the fiscal year wraps up, Star Group, L.P. (NYSE: SGU), a respected home energy distributor, shares its financial performance that ended on September 30, 2024. Amidst the prevailing challenges in the energy market, the company continues its commitment to delivering quality services while adapting to market...

Continue Reading
Krystal Biotech Launches Clinical Trial for Eye Therapy KB801

Updated Category News Views 148

Krystal Biotech Begins Phase 1/2 Trial of KB801 Krystal Biotech, Inc. (NASDAQ: KRYS) has recently announced exciting developments in its ophthalmology pipeline with the initiation of a Phase 1/2 clinical trial for KB801, aimed at treating neurotrophic keratitis (NK). This 2:1 randomized, double-masked, multicenter, placebo-controlled study, named EMERALD-1, marks a...

Continue Reading
Key Updates on the Annual General Meeting of Ignitis Group

Updated Category News Views 163

Exciting Updates for the Ignitis Group Shareholders The retained earnings figure for AB “Ignitis grup?” has been amended for the upcoming Annual General Meeting. It now stands at EUR 320,319,368.41, following a revision made only to the English version of the document. This adjustment reflects the company’s commitment to transparency and accuracy in their financial...

Continue Reading
Transforming Connectivity: The Future of mmWave Sensors Growth

Updated Category News Views 104

The mmWave sensors market was set on a blistering growth path back in 2023, valued at around USD 0.25 billion. By the time you fast-forward to 2032, projections had it skyrocketing to USD 2.40 billion, boasting a staggering CAGR of 28.59% from 2024 through 2032. You'd think this kind of momentum would have traders buzzing—oh wait, they were, especially as the push for...

Continue Reading